Please login to the form below

Not currently logged in
Email:
Password:

AZ and Medimmune bolsters immuno-oncology leadership

Dr Jean-Charles Soria and Dr Geoffrey Kim join the company

AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria, respectively.

Kim and his team will focus on the development of the company’s late-stage immuno-oncology combinations programme, aiming to develop combination regimens that will deliver innovative medicines to patients.

He most recently served the US Food and Drug Administration (FDA) as its director, division of oncology products in the office of haematology oncology products since 2015 and also had roles at the National Cancer Institute (NCI).

Soria also taking up a leadership role within AZ’s global biologics research and development arm MedImmune, will lead a team responsible for the group’s strategy, growth, and advancement of the early oncology biologics portfolio.

Prior to joining MedImmune, he served as a professor of medicine and medical oncology at South-Paris University and has also served as chair of the drug development department at the Institut Gustave Roussy - a leading cancer-research institute.

He will join the company in early September succeeding Dr David Berman, who has been appointed to the new role of senior vice president, immuno-oncology franchise.

8th August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics